| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 23.10. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Diagnostear Technologies Inc: Diagnostear receives positive results from TeaRx study | 4 | Stockwatch | ||
| DIAGNOSTEAR TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 10.09. | DiagnosTear Technologies Inc.: DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis | 394 | Newsfile | Final study results demonstrate 89% sensitivity, 83.3% specificity compared with quantitative ELISA reference testing for IgE detection.Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026)... ► Artikel lesen | |
| 03.09. | Diagnostear Technologies Inc: Diagnostear files FDA presubmission for TeaRx Red Eye | 1 | Stockwatch | ||
| 31.08. | Diagnostear Technologies Inc: Diagnostear arranges $1.4-million private placement | 1 | Stockwatch | ||
| 31.08. | DiagnosTear announces private placement of up to C$1.4M | 1 | Investing.com | ||
| 10.07. | Diagnostear Technologies Inc: Diagnostear analyzes TeaRx, enzyme immunoassay | 1 | Stockwatch | ||
| 09.07. | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx Red Eye and Quantitative ELISA Testing | 657 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 05.06. | Diagnostear Technologies Inc: Diagnostear publishes TeaRx dry-eye study results | 3 | Stockwatch | ||
| 05.06. | DiagnosTear Technologies Inc.: DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx Clinical Study in Current Eye Research Journal | 645 | Newsfile | Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to... ► Artikel lesen | |
| 15.05. | Bahnbrechende KI: Ohne Nadeln zum Blutbild! | bullVestor | |||
| 12.05. | DiagnosTear Technologies Inc.: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics | 868 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies... ► Artikel lesen | |
| 08.05. | Diagnostear Technologies Inc: Diagnostear shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 07.05. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Results of AGM | 519 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general... ► Artikel lesen | |
| 05.05. | Diagnostear Technologies Inc: Diagnostear Technologies extends warrants | 17 | Stockwatch | ||
| 21.04. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting | 784 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR")... ► Artikel lesen | |
| 26.02. | DiagnosTear Technologies Inc.: DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx Red Eye | 692 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 20.02. | DiagnosTear Technologies Inc.: DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical | 1.108 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics... ► Artikel lesen | |
| 22.01. | DiagnosTear Technologies Inc.: DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx in India | 597 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 17.01. | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx Red Eye | 1.035 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 18.12.25 | DiagnosTear Technologies Inc.: DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count | 997 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,100 | +1,75 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - JPMorgan hat Fresenius nach Gesprächen mit der Investor-Relations-Abteilung mit einem Kursziel von 55,20 Euro auf "Overweight" belassen. Die Aktien stehen zudem auf der... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,860 | +0,24 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 35,540 | +1,25 % | 12 Prozent bessere Testleistung: Wie ZEISS das Zusammenspiel von Brillenglas und Gehirn untersucht | ||
| INTUITIVE SURGICAL | 404,20 | +0,05 % | Intuitive Surgical Inc. Reports Fall In Q3 Profit | SUNNYVALE (dpa-AFX) - Intuitive Surgical Inc. (ISRG) revealed earnings for third quarter that Drops, from last yearThe company's earnings totaled $522.8 million, or $1.49 per share. This compares... ► Artikel lesen | |
| DRAEGERWERK | 100,60 | +2,24 % | Was jetzt entscheidend wird bei Desert Gold, Draegerwerk und Verbio | Erstellt und veröffentlicht im Auftrag von Desert Gold Ventures Inc. Starke Kursbewegungen, operative Meilensteine und veränderte Gewinnperspektiven prägen derzeit das Bild bei drei sehr unterschiedlichen... ► Artikel lesen | |
| MEDTRONIC | 85,60 | +0,42 % | Medtronic Reports Positive Real-World Data For Cardiac Ablation Systems | WASHINGTON (dpa-AFX) - Medtronic (MDT) reported positive results from two large real-world registries evaluating its Sphere-9 Catheter and the PulseSelect Pulsed Field Ablation (PFA) System... ► Artikel lesen | |
| GERRESHEIMER | 31,340 | -2,06 % | Gerresheimer-Aktie: Trotz der deutlichen Kurserholung noch einsteigen? | Die Gerresheimer-Aktie entwickelt sich seit dem Kurseinbruch im Februar sehr erfreulich. Notierte sie damals noch bei etwa 16 €, steht sie am Montag aktuell bei rund 30,10 €. Damit hat sich der Kurs... ► Artikel lesen | |
| THERMO FISHER | 600,00 | -0,33 % | dpa-AFX-Überblick: UNTERNEHMEN vom 22.10.2026 - 15.15 Uhr | ROUNDUP 2: Musk schwärmt nach Tesla-Gewinneinbruch von Robotern - Aktie fällt Das Papier verlor im vorbörslichen US-Handel am Donnerstag fast fünf Prozent auf 368 Dollar. Damit war das Plus vom Vortag... ► Artikel lesen | |
| TELADOC HEALTH | 5,580 | -1,55 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| HIMS & HERS HEALTH | 24,740 | 0,00 % | Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit | ||
| BRIGHTSPRING HEALTH SERVICES | 60,11 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,460 | +3,27 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| GENEDX | 56,08 | -0,12 % | GeneDx plans to add long-read genome sequencing to portfolio | ||
| ALIGNMENT HEALTHCARE | 8,060 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors | ||
| PRIVIA HEALTH GROUP | 22,410 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen |